secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0000950170-24-117946
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D
--------------------------------------------------------------------------------

- First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.
- Islet engraftment 3-5x higher than comparable subjects on tacrolimus-based immunosuppression, suggesting less toxicity to transplanted cells.
- Treatment was generally well tolerated with no unexpected adverse events or severe hypoglycemic episodes.
- Data to be presented at IPITA/HSCI/Breakthrough T1D Stem Cells Summit on Oct 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024117946/0000950170-24-117946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024117946/eldn-20241029.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer